FDA Admits to Massive Conflict of Interest
October 13, 2009
The U.S. Food and Drug Administration admitted that four New Jersey congressmen and its own former commissioner unduly influenced the process that led to its decision last year to approve a patch for injured knees.
The agency’s scientific reviewers repeatedly and unanimously decided that the device, known as Menaflex and manufactured by ReGen Biologics, was unsafe because it often failed, forcing patients to get another operation.
But after receiving what an FDA report described as “extreme,” “unusual” and persistent pressure from four congressmen, agency managers overruled the scientists and approved the device for sale in December. All four legislators made their inquiries within a few months of receiving significant campaign contributions from ReGen, which is based in New Jersey.
The agency has never before publicly questioned the process behind one of its approvals, never admitted that a regulatory decision was influenced by politics, and never accused a former commissioner of questionable conduct.